Severe exacerbations of COPD, ie, those leading to hospitalization, have profound clinical
implications for patients and significant economic consequences for society. The prevalence …

While the pharmacological management of chronic obstructive pulmonary disease (COPD)
has evolved from the drugs used to treat asthma, the treatment models are different and the …

Objective To examine the effect of β blockers in the management of chronic obstructive
pulmonary disease (COPD), assessing their effect on mortality, hospital admissions, and …

Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a
network meta‐analysis - Kew, KM - 2014 | Cochrane Library Skip to Content Cookies Our site …

Background In clinical trials, the use of inhaled corticosteroids is associated with an
increased risk of pneumonia in people with COPD, but whether the same is true for people …

Background The active-treatment comparative safety information for all inhaled medications
in patients with chronic obstructive pulmonary disease (COPD) is limited. We aimed to …

Background Evaluation of cardiovascular safety for new therapies for COPD is important
because of a high prevalence of cardiac comorbidities in the COPD population. Hence, we …

Clinicians should consider the long-term risks of pneumonia with the use of inhaled
corticosteroids in patients with COPD. Adequately powered long-term head-to-head trials …

Background Long‐acting beta 2‐agonists and inhaled corticosteroids can be used as
maintenance therapy by patients with moderate to severe chronic obstructive pulmonary …

Randomized controlled trials (RCTs) are preferred by payers for health technology
assessments and coverage decisions. However, the inclusion of a highly selective patient …